Tamoxifen resistance in a breast cancer xenograft model coincides with a switch from an ER+/PgR+ to an ER+/PgR- phenotype accompanied by EGFR/HER2 activation

被引：0
|
作者：
Massarweh, S
Osborne, CK
Wakeling, AE
Schiff, R
机构：
[1] Baylor Coll Med, Houston, TX 77030 USA
[2] Astra Zeneca, Macclesfield, Cheshire, England
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2004年 / 88卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S18 / S18
页数：1
相关论文
共 50 条
  • [21] ER+/PR− phenotype exhibits more aggressive biological features and worse outcome compared with ER+/PR+ phenotype in HER2-negative inflammatory breast cancer
    Yunbo Luo
    Qingyun Li
    Jiang Fang
    Chaoying Pan
    Lingxing Zhang
    Xia Xu
    Shuangqiang Qian
    Xiaobo Zhao
    Lingmi Hou
    Scientific Reports, 14
  • [22] Inhibition of mutant HER2 results in synthetic lethality when combined with ER antagonists in ER+/HER2 mutant human breast cancer cells
    Croessmann, S.
    Zabransky, D. J.
    Cutler, R. E., Jr.
    Lalani, A. S.
    Park, B. H.
    Arteaga, C. L.
    CANCER RESEARCH, 2017, 77
  • [23] An AI system for predicting ER/PGR/HER2 status from H&E slides in breast cancer
    Gamble, P.
    Jaroensri, R.
    Tan, F.
    Moran, M.
    Steiner, D. F.
    Mermel, C. H.
    Chen, P. C.
    VIRCHOWS ARCHIV, 2020, 477 : S37 - S37
  • [24] Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies
    Nayar, Utthara
    Cohen, Ofir
    Kapstad, Christian
    Cuoco, Michael S.
    Waks, Adrienne G.
    Wander, Seth A.
    Painter, Corrie
    Freeman, Samuel
    Persky, Nicole S.
    Marini, Lori
    Helvie, Karla
    Oliver, Nelly
    Rozenblatt-Rosen, Orit
    Ma, Cynthia X.
    Regev, Aviv
    Winer, Eric P.
    Lin, Nancy U.
    Wagle, Nikhil
    NATURE GENETICS, 2019, 51 (02) : 207 - +
  • [25] Mechanisms of resistance to estrogen receptor modulators in ER+/HER2-advanced breast cancer
    Zhang, Jin
    Wang, Qianying
    Wang, Qing
    Cao, Jiangran
    Sun, Jiafu
    Zhu, Zhengmao
    CELLULAR AND MOLECULAR LIFE SCIENCES, 2020, 77 (04) : 559 - 572
  • [26] Complete disappearance of ER+/HER2+breast cancer xenografts with the combination of gefitinib, trastuzumab, and pertuzumab to block HER2 cross-talk with ER and restore tamoxifen inhibition
    Arpino, G
    Weiss, H
    Wakeling, AE
    Osborne, K
    Schiff, R
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S15 - S15
  • [27] Receptor status (ER, PgR and HER2) discordance between primary tumor and locoregional recurrence in breast cancer
    Zurrida, S.
    Montagna, E.
    Naninato, P.
    Colleoni, M.
    Goldhirsch, A.
    ANNALS OF ONCOLOGY, 2011, 22 (02) : 479 - U259
  • [28] A phase II trial of letrozole and trastuzumab for ER and/or PgR and HER2 positive metastatic breast cancer.
    Wong, ZW
    Isaacs, C
    Harris, L
    Ellis, MJ
    BREAST CANCER RESEARCH AND TREATMENT, 2003, 82 : S106 - S107
  • [29] Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2-Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2-Breast Cancer
    Rosswag, Sven
    Cotarelo, Cristina L.
    Pantel, Klaus
    Riethdorf, Sabine
    Sleeman, Jonathan P.
    Schmidt, Marcus
    Thaler, Sonja
    CANCERS, 2021, 13 (08)
  • [30] The multigene signature MammaPrint impacts on multidisciplinary team decisions in ER+, HER2− early breast cancer
    R Exner
    Z Bago-Horvath
    R Bartsch
    M Mittlboeck
    V P Retèl
    F Fitzal
    M Rudas
    C Singer
    G Pfeiler
    M Gnant
    R Jakesz
    P Dubsky
    British Journal of Cancer, 2014, 111 : 837 - 842
12345